Cecilia G Ethun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4468349/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. Ca-A Cancer Journal for Clinicians, 2017, 67, 362-377.	157.7	364
2	Transplantation Versus Resection for Hilar Cholangiocarcinoma. Annals of Surgery, 2018, 267, 797-805.	2.1	137
3	Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms. JAMA Surgery, 2017, 152, 19.	2.2	82
4	Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival. JAMA Surgery, 2017, 152, 143.	2.2	74
5	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons, 2016, 222, 480-490.	0.2	71
6	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2017, 24, 1343-1350.	0.7	68
7	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.2	61
8	Elevated NLR in gallbladder cancer and cholangiocarcinoma – making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 950-957.	0.1	50
9	The importance of surgical margins in pancreatic cancer. Journal of Surgical Oncology, 2016, 113, 283-288.	0.8	49
10	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2018, 25, 1140-1149.	0.7	48
11	Defining Early Recurrence of Hilar Cholangiocarcinoma After Curativeâ€intent Surgery: A Multiâ€institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery, 2018, 42, 2919-2929.	0.8	48
12	Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. Journal of Surgical Oncology, 2016, 114, 440-445.	0.8	47
13	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	0.7	44
14	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon, 2017, 83, 679-686.	0.4	44
15	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Annals of Surgical Oncology, 2016, 23, 3016-3023.	0.7	42
16	The conundrum of < 2-cm pancreatic neuroendocrine tumors: AÂpreoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019, 166, 15-21.	1.0	34
17	Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 611-618.	0.7	34
18	The importance of surgical margins in melanoma. Journal of Surgical Oncology, 2016, 113, 339-345.	0.8	32

#	Article	IF	CITATIONS
19	Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. Journal of Surgical Oncology, 2018, 117, 1267-1277.	0.8	32
20	Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. Journal of Surgical Oncology, 2016, 114, 176-180.	0.8	30
21	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. Journal of Gastrointestinal Surgery, 2017, 21, 1245-1253.	0.9	30
22	Small bowel neuroendocrine tumors: A critical analysis of diagnostic workâ€up and operative approach. Journal of Surgical Oncology, 2016, 114, 671-676.	0.8	29
23	The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery, 2018, 163, 726-731.	1.0	29
24	Recurrence patterns after resection of retroperitoneal sarcomas: An eightâ€institution study from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 340-347.	0.8	29
25	Routine portâ€site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multiâ€institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2017, 115, 805-811.	0.8	28
26	Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. Journal of the American College of Surgeons, 2017, 224, 406-413.	0.2	28
27	Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. European Journal of Surgical Oncology, 2018, 44, 810-815.	0.5	28
28	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. Hpb, 2018, 20, 332-339.	0.1	27
29	Role of radiation therapy for retroperitoneal sarcomas: An eightâ€institution study from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 1227-1234.	0.8	26
30	Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2017, 19, 1104-1111.	0.1	25
31	Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. Annals of Surgical Oncology, 2017, 24, 2770-2776.	0.7	25
32	The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multiâ€institutional propensity score analysis from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 332-339.	0.8	25
33	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 417-425.	0.7	21
34	A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?. Journal of Surgical Oncology, 2016, 114, 576-580.	0.8	19
35	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World Journal of Surgery, 2017, 41, 224-231.	0.8	19
36	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. Annals of Surgical Oncology, 2019, 26, 3542-3549.	0.7	19

#	Article	IF	CITATIONS
37	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2019, 26, 1814-1823.	0.7	19
38	Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multiâ€institutional analysis of the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 122, 1189-1198.	0.8	19
39	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 4205-4213.	0.7	19
40	The value of a crossâ€discipline teamâ€based approach for resection of renal cell carcinoma with IVC tumor thrombus: A report of a large, contemporary, singleâ€institution experience. Journal of Surgical Oncology, 2018, 118, 1219-1226.	0.8	18
41	Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 793-799.	0.1	17
42	Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. Journal of Gastrointestinal Surgery, 2016, 20, 1444-1452.	0.9	16
43	The role of radiation therapy and margin width in localized softâ€tissue sarcoma: Analysis from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 325-331.	0.8	16
44	The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eightâ€institution study of 349 patients over 15 years. Journal of Surgical Oncology, 2017, 115, 784-787.	0.8	15
45	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	0.7	15
46	Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. Annals of Surgical Oncology, 2018, 25, 290-298.	0.7	15
47	Lung Surveillance Strategy for High-Grade Soft Tissue Sarcomas: Chest X-Ray or CT Scan?. Journal of the American College of Surgeons, 2019, 229, 449-457.	0.2	14
48	Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?. Journal of the American College of Surgeons, 2018, 227, 357-366e3.	0.2	13
49	Evaluation and management of incidental gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 37-37.	0.4	13
50	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. American Surgeon, 2017, 83, 761-768.	0.4	12
51	Staging laparoscopy among three subtypes of extraâ€hepatic biliary malignancy: a 15â€year experience from 10 institutions. Journal of Surgical Oncology, 2019, 119, 288-294.	0.8	12
52	The Oncologic Impact of Postoperative Complications Following Resection of Truncal and Extremity Soft Tissue Sarcomas. Annals of Surgical Oncology, 2017, 24, 3574-3586.	0.7	11
53	Determination of Resectability. Surgical Clinics of North America, 2016, 96, 163-181.	0.5	10
54	Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10â€institution study from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2018, 117, 1638-1647.	0.8	10

#	Article	IF	CITATIONS
55	Is a Nomogram Able to Predict Postoperative Wound Complications in Localized Soft-tissue Sarcomas of the Extremity?. Clinical Orthopaedics and Related Research, 2020, 478, 550-559.	0.7	10
56	<i>Colon and Rectal Neuroendocrine Tumors: Are They Really One Disease? A Single-Institution Experience over 15 Years</i> . American Surgeon, 2018, 84, 717-726.	0.4	9
57	The Prognostic Value of Lymphovascular Invasion in Truncal and Extremity Soft Tissue Sarcomas: An Analysis from the National Cancer Database. Annals of Surgical Oncology, 2019, 26, 4723-4729.	0.7	9
58	Identifying the barriers to gastric cancer care at safetyâ€net hospitals: A novel comparison of a safetyâ€net hospital to a neighboring quaternary referral academic center in the same healthcare system. Journal of Surgical Oncology, 2019, 119, 64-70.	0.8	9
59	Renal Function After Retroperitoneal Sarcoma Resection with Nephrectomy: A Matched Analysis of the United States Sarcoma Collaborative Database. Annals of Surgical Oncology, 2021, 28, 1690-1696.	0.7	9
60	A multiâ€institutional validation study of prognostic nomograms for retroperitoneal sarcoma. Journal of Surgical Oncology, 2021, 124, 829-837.	0.8	9
61	Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Journal of Surgical Oncology, 2016, 114, 336-341.	0.8	8
62	Outcomes in Patients with Renal Cell Carcinoma Undergoing Inferior Vena Cava Ligation without Reconstruction versus Thrombectomy: A Retrospective, Case Controlled Study. Journal of Urology, 2021, 205, 383-391.	0.2	8
63	Outcomes of palliativeâ€intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 121, 1140-1147.	0.8	7
64	A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. Journal of Surgical Oncology, 2021, 124, 1477-1484.	0.8	7
65	Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years. Journal of Surgical Oncology, 2016, 114, 163-169.	0.8	6
66	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. Journal of Surgical Research, 2019, 233, 154-162.	0.8	6
67	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. Journal of Gastrointestinal Surgery, 2020, 24, 1138-1148.	0.9	5
68	Perioperative Versus Adjuvant Chemotherapy in the Management of Incidentally Found Gallbladder Cancer (OPT-IN). Annals of Surgical Oncology, 2022, 29, 37-38.	0.7	5
69	A novel, simplified, externally validated staging system for truncal/extremity soft tissue sarcomas: An analysis of the US Sarcoma Collaborative database. Journal of Surgical Oncology, 2018, 118, 1135-1141.	0.8	4
70	Retroperitoneal sarcoma perioperative risk stratification: A United States Sarcoma Collaborative evaluation of the ACSâ€NSQIP risk calculator. Journal of Surgical Oncology, 2020, 122, 795-802.	0.8	4
71	<i>The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?</i> . American Surgeon, 2018, 84, 56-62.	0.4	3
72	Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. Journal of Surgical Research, 2020, 245, 577-586.	0.8	3

#	Article	lF	CITATIONS
73	Impact of resection margin on outcomes in highâ€grade soft tissue sarcomas of the extremity—A USSC analysis. Journal of Surgical Oncology, 2021, 123, 479-488.	0.8	3
74	Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. Journal of Surgical Research, 2018, 231, 248-256.	0.8	2
75	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. Surgery, 2020, 168, 760-767.	1.0	2
76	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. Surgical Oncology, 2020, 34, 292-297.	0.8	2
77	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Surgical Oncology, 2020, 35, 460-465.	0.8	1
78	ASO Author Reflections: Incorporating Lymphovascular Invasion to Improve the Prognostic Reliability of the T-Staging System for Adrenocortical Carcinoma—A Multicenter Study. Annals of Surgical Oncology, 2018, 25, 862-863.	0.7	0
79	Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years Journal of Clinical Oncology, 2016, 34, 228-228.	0.8	0
80	A multi-center study of 349 pancreatic mucinous cystic neoplasms: Preoperative risk factors for adenocarcinoma Journal of Clinical Oncology, 2016, 34, 231-231.	0.8	0
81	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	Ο